A unique pharmaceutical company
Orphan Europe, part of the Recordati group, is a unique pharmaceutical company focusing on the research and development of orphan medicinal products. Since 1990 we have used big thinking and extensive know-how on behalf of people affected by rare diseases. Patients and their families are central to our planning, our thinking and our actions.
Read more >>
News and events
The decree implementing French Law No. 2011-2012 on the Strengthening of Health Protection for Medicinal and Health Products, also known as the French Sunshine Act, was issued on 21 May 2013. The Sunshine Act was adopted to ensure transparency of decision-making within the health care sector and to prevent conflicts of interest between stakeholders. Its aim is to specify the scope of disclosure obligations, which affect all agreements concluded between health care professionals and companies, as well as every benefit in kind or in cash exceeding €10.
Orphan Europe publishes, in French, its agreements and benefits with French health care professionals on a dedicated public website
Due to manufacturing issues there is currently a worldwide Pedea® drug shortage. Pedea® is an orphan drug approved for the treatment of haemodynamically significant patent ductus arteriosus in premature newborn infants of less than 34 weeks of gestational age.
Please refer to your local authorities for more information.